InvisiDerm Announces Zero Adverse Effects Two Years After Successful D`OXYVA® Landmark Human Clinical Study - New Randomized Human Clinical Study at Penn State University | InvisiDerm Announces Zero Adverse Effects |
Pasadena, California (PRWEB) June 10, 2014 -- InvisiDerm Healthcare Announces Zero Adverse Effects have been reported two years after its groundbreaking transdermal delivery study in diabetic and non-diabetic people and one year after results were presented to scientific community at international medical conference; potential seen for a wide range of direct health and beauty applications for widespread conditions.